Home MAPK KRas inhibitor VS-7375 (GFH375)

research use only

VS-7375 (GFH375) KRas inhibitor

Cat.No.E6638

GFH375(VS-7375) is an oral small-molecule inhibitor that selectively targets KRAS G12D in both its active (GTP-bound) and inactive (GDP-bound) forms. This dual-state inhibition results in stronger tumor suppression compared to single-state inhibitors. It exhibits potent anti-proliferative and anti-tumor effects in KRAS G12D-mutant models, including an intracranial GP2D tumor model.
VS-7375 (GFH375) KRas inhibitor Chemical Structure

Molecular Weight: 685.08

Jump to

Quality Control

Batch: E663801 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 98.455%
98.455

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (145.96 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 685.08 Formula

C31H27ClD3F6N7O2

 Storage (From the date of receipt)
CAS No. Download SDF Storage of Stock Solutions

Read more about storage stability stock solution

Mechanism of Action

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-10)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07668752 RECRUITING
KRAS G12D Mutation; NSCLC (Non-small Cell Lung Cancer)
Genfleet Therapeutics (Shanghai) Inc.
 2026-07-27 PHASE3
NCT07020221 RECRUITING
Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor, Adult; G12D Mutated KRAS
Verastem, Inc.
 2025-06-24 PHASE1; PHASE2
NCT07784374 NOT_YET_RECRUITING
Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
 2026-08-31 PHASE2
NCT06500676 RECRUITING
KRAS G12D Mutations; Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
 2024-07-09 PHASE1; PHASE2
NCT07026916 WITHDRAWN
Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
 2025-08 PHASE2
NCT07259590 RECRUITING
Advanced Solid Tumors Cancer; PDAC; CRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc.
 2025-10-21 PHASE1; PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map